Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exemestane (Primary) ; Fulvestrant (Primary) ; GS 5829 (Primary)
Indications Advanced breast cancer; Diffuse large B cell lymphoma; Lymphoma; Peripheral T-cell lymphoma; Solid tumours
Focus Adverse reactions
Sponsors Gilead Sciences

11 Jul 2022 Results from NCT02392611 and NCT02607228; assessing safety and efficacy, published in the Clinical Cancer Research
18 Oct 2017 Status changed from active, no longer recruiting to completed.
07 Jun 2017 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com